A Post-Marketing Surveillance Study on the Safety And Effectiveness of Bendamustine Hydrochloride Among Adult Filipino Patients With Chronic Lymphocytic Leukemia

Trial Profile

A Post-Marketing Surveillance Study on the Safety And Effectiveness of Bendamustine Hydrochloride Among Adult Filipino Patients With Chronic Lymphocytic Leukemia

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Bendamustine (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 28 Jun 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 08 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top